Seasonal influenza nanoparticle vaccine - Novavax

Drug Profile

Seasonal influenza nanoparticle vaccine - Novavax

Alternative Names: Influenza nanoparticle vaccine - Novavax; NanoFlu

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novavax
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Influenza virus infections

Most Recent Events

  • 19 Sep 2017 Phase-I/II clinical trials in Influenza virus infections (Prevention, In the elderly) in USA (Parenteral)
  • 23 Aug 2017 Immunogenicity data from a preclinical trial in Influenza released by Novavax
  • 08 Aug 2017 Immunogenicity data from a preclinical trial in Influenza virus infections (Prevention) released by Novavax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top